BR0209922A - Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero - Google Patents

Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero

Info

Publication number
BR0209922A
BR0209922A BR0209922-5A BR0209922A BR0209922A BR 0209922 A BR0209922 A BR 0209922A BR 0209922 A BR0209922 A BR 0209922A BR 0209922 A BR0209922 A BR 0209922A
Authority
BR
Brazil
Prior art keywords
treating
mammal
patient
endothelial cell
medical condition
Prior art date
Application number
BR0209922-5A
Other languages
English (en)
Inventor
Hamdi K Hamdi
Jeffrey H Tavis
Raquel Castellon
Original Assignee
Hamdi K Hamdi
Jeffrey H Tavis
Raquel Castellon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamdi K Hamdi, Jeffrey H Tavis, Raquel Castellon filed Critical Hamdi K Hamdi
Publication of BR0209922A publication Critical patent/BR0209922A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

"MéTODOS PARA TRATAR UMA CONDIçãO MéDICA QUE ENVOLVE A ANGIOGêNESE EM UM PACIENTE, PARA INIBIR A VASCULARIZAçãO DE CéLULAS ENDOTELIAIS, E PARA TRATAR CâNCER EM UM MAMìFERO". Métodos para inibir a anglogenese são divulgados e compreendem a administração de oleouropeína e os produtos da sua hidrólise em quantidades terapeuticamente eficazes. Os métodos e composições da presente invenção são particularmente eficazes em inibir a vascularização de células endoteliais e podem ser utilizados para tratar uma ampla variedade de cânceres, doenças oculares e condições inflamatórias.
BR0209922-5A 2001-05-23 2002-05-22 Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero BR0209922A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29294701P 2001-05-23 2001-05-23
PCT/US2002/016191 WO2002094193A1 (en) 2001-05-23 2002-05-22 Methods for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
BR0209922A true BR0209922A (pt) 2004-07-27

Family

ID=23126933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209922-5A BR0209922A (pt) 2001-05-23 2002-05-22 Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero

Country Status (16)

Country Link
US (1) US6632798B2 (pt)
EP (1) EP1397105B1 (pt)
JP (1) JP2005508856A (pt)
CN (1) CN1315479C (pt)
AT (1) ATE333882T1 (pt)
AU (1) AU2002311985B9 (pt)
BR (1) BR0209922A (pt)
CA (1) CA2447231A1 (pt)
DE (1) DE60213407T2 (pt)
DK (1) DK1397105T3 (pt)
ES (1) ES2266512T3 (pt)
IL (1) IL158899A0 (pt)
MX (1) MXPA03010528A (pt)
PT (1) PT1397105E (pt)
WO (1) WO2002094193A1 (pt)
ZA (1) ZA200308763B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3629939B2 (ja) * 1998-03-18 2005-03-16 セイコーエプソン株式会社 トランジスタ回路、表示パネル及び電子機器
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7468355B2 (en) * 2002-05-22 2008-12-23 H2Rc Corporation Methods for inhibiting cancer and scar formation
FR2853549B1 (fr) * 2003-04-11 2007-11-09 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
US20070122492A1 (en) * 2004-11-18 2007-05-31 Stephen Behr Plant extracts and dermatological uses thereof
US20060100368A1 (en) * 2004-11-08 2006-05-11 Park Edward H Elastomer gum polymer systems
KR101351674B1 (ko) * 2005-09-30 2014-01-14 디에스엠 아이피 어셋츠 비.브이. 폴리페놀을 함유하는 신규 조성물
ES2289897B1 (es) * 2005-11-08 2008-12-16 Laboratorios Belmac, S.A. Composicion para administracion transdermica de agentes fisiologicamente activos.
ES2274721B1 (es) * 2005-11-03 2008-06-01 Laboratorios Belmac, S.A. Nuevo agente terapeutico para el tratamiento de una condicion asociada a la enfermedad vascular periferica.
EP1981593A2 (en) * 2006-02-01 2008-10-22 Philips Intellectual Property & Standards GmbH Improved radiation therapy planning procedure
JP5339373B2 (ja) * 2006-07-14 2013-11-13 ディーエスエム アイピー アセッツ ビー．ブイ． 組成物および炎症障害の治療、共治療または予防のためのその使用
JP5175481B2 (ja) * 2006-10-23 2013-04-03 エーザイフード・ケミカル株式会社 軟骨再生促進剤
KR100834444B1 (ko) * 2007-01-15 2008-06-09 원광대학교산학협력단 물푸레나무로부터 분리된 올레우로페인 화합물을 포함하는톡소플라즈마증 예방 및 치료용 약학조성물
US20100130620A1 (en) * 2007-04-18 2010-05-27 Jiankang Liu Novel use of hydroxytyrosol and olive extracts/concentrates containing it
WO2008139009A1 (es) * 2007-05-10 2008-11-20 Universidad De Malaga Piridotienotriazinas como compuestos antiangiogenicos
JP5138341B2 (ja) * 2007-11-07 2013-02-06 日本メナード化粧品株式会社 抗アレルギー剤
KR101098952B1 (ko) * 2009-05-08 2011-12-28 한국생명공학연구원 갈잎떨기나무 추출물을 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 조성물
WO2011141611A1 (es) 2010-05-14 2011-11-17 Sanidad Y Residencias 21, S.A., Composiciones de oleuropeína para cicatrización de heridas y úlceras en ancianos y/o diabéticos
ES2349976B1 (es) * 2009-05-14 2011-11-10 Sanidad Y Residencias 21 Sa Utilizacion de extractos de hojas de olivo en una composicion farmaceutica para inducir angiogenesis y vasculogenesis.
US8092843B2 (en) * 2009-09-23 2012-01-10 East Park Research, Inc. Method and composition for cutaneous treatment of herpes simplex infections
ITMI20111042A1 (it) * 2011-06-09 2012-12-10 Flavia Franconi Frazioni standardizzate da olea europaea l. e loro uso genere specifico per la prevenzione delle patologie invecchiamento-correlate
US9073824B2 (en) 2012-01-26 2015-07-07 Prairie Pharms, Llc Method for cultivation of Monarda fistulosa for production of thymoquinone
KR101269490B1 (ko) * 2012-07-09 2013-05-30 연세대학교 산학협력단 세코이리도이드 글루코사이드 유도체를 유효성분으로 포함하는 탈모의 예방 또는 치료용 조성물
CN102942605B (zh) * 2012-11-30 2016-06-15 沈阳药科大学 清香藤中环烯醚萜类化合物的制备方法及其应用
CN104784241A (zh) * 2014-01-22 2015-07-22 上海御先医药科技有限公司 一种橄榄树叶粗提物的新用途
CN104473949A (zh) * 2014-11-11 2015-04-01 济南星懿医药技术有限公司 一种治疗肝癌的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4139196A (en) * 1994-11-07 1996-05-31 William R. Fredrickson Method and composition for antiviral therapy
US6197308B1 (en) * 1998-07-23 2001-03-06 Creagri L.L.C. Water-soluble extract from olives
US6358542B2 (en) * 1999-12-20 2002-03-19 Usana, Inc. Antioxidant compositions extracted from olives and olive by-products
AU2000258901A1 (en) * 2000-04-06 2001-10-23 Nicholas V. Perricone Treatment of skin damage using olive oil polyphenols
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders

Also Published As

Publication number Publication date
CA2447231A1 (en) 2002-11-28
CN1531435A (zh) 2004-09-22
DE60213407D1 (de) 2006-09-07
MXPA03010528A (es) 2005-04-19
ZA200308763B (en) 2004-05-26
DK1397105T3 (da) 2006-11-27
IL158899A0 (en) 2004-05-12
EP1397105B1 (en) 2006-07-26
JP2005508856A (ja) 2005-04-07
WO2002094193A1 (en) 2002-11-28
ATE333882T1 (de) 2006-08-15
AU2002311985B2 (en) 2008-04-10
EP1397105A1 (en) 2004-03-17
AU2002311985B9 (en) 2008-07-10
US6632798B2 (en) 2003-10-14
ES2266512T3 (es) 2007-03-01
CN1315479C (zh) 2007-05-16
PT1397105E (pt) 2006-12-29
DE60213407T2 (de) 2007-08-23
US20030004117A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
BR0110420A (pt) Agonistas muscarìnicos
GB9807639D0 (en) Anti-inflammatory agents
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
NZ610068A (en) Compositions comprising povidone-iodine
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
BG105880A (en) Compounds useful as anti-inflammatory agents
BRPI0516177B8 (pt) oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
BRPI0416934A (pt) método para reduzir a gravidade dos distúrbios das células plasmáticas ou para o tratamento dos distúrbios das células plamáticas, método para reduzir a dose de um agente citotóxico, e, método para reduzir a produção de il-6 ou de vegf pelos fibroblastos que se acham em contato com as células plasmáticas cancerosas
WO2005060960A3 (en) Use of histamine to treat bone disease
BR0313589A (pt) Uso de extrato de germe de trigo fermentado como agente antiinflamatório
WO2006128179A3 (en) Use of matrilin-1 for the treatment of angiogenesis related diseases
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
NZ600187A (en) Pharmaceutical composition for treating cutaneous burns
DE60005548D1 (de) Zusammensetzung enthaltend einen extrakt aus perna canaliculus, methylsulfonylmethan und glucosamine und verwendung
SE9303612D0 (sv) New use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011